Modified FOLFOX plus/minus Nivolumab and Ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction - A randomized phase 2 trial
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms MOONLIGHT
- 04 Jun 2019 Results (data cut off: February 2019; n=28) presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 08 Nov 2018 Status changed from not yet recruiting to recruiting.
- 23 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 1 Oct 2018.